DLA Piper has advised Kartos Therapeutics. Kartos Therapeutics, a US-based clinical stage biotechnology company, has entered into an agreement to be acquired by the French biopharmaceutical...
Ipsen Acquires Kartos Therapeutics in US$1.75 Billion Deal
Motorola Solutions to Acquire D-Fend Solutions for $1.5 Billion
DLA Piper has advised Motorola Solutions, Inc.; Wilson Sonsini Goodrich & Rosati has advised Centerview Partners LLC, financial advisor to Motorola Solutions. Motorola Solutions, Inc. has...
Merck’s $3.9 Billion Acquisition of SpringWorks Therapeutics
Sullivan & Cromwell advised Merck KGaA, Darmstadt, Germany, while Goodwin Procter advised SpringWorks Therapeutics on the transaction. Skadden advised Centerview Partners and Goldman Sachs & Co....
Silver Lake and GIC’s $1.7 Billion Acquisition of Zuora
Goodwin Procter advised the Special Committee of Zuora and Freshfields US advised Zuora, Simpson Thacher & Bartlett advised Silver Lake, Dechert advised GIC, Sullivan & Cromwell...
Samsung Display’s $218 Million Acquisition of eMagin
O’Melveny advised Samsung Display Co., Ltd on the transaction, while White & Case and Goodwin Procter advised eMagin. Samsung Display Co., Ltd, a subsidiary of Samsung...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
Senti Biosciences’ Business Combination with Dynamics Special Purpose Corp.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
Pear Therapeutics’ $1.6 Billion Business Combination with Thimble Point Acquisition Corp.
Goodwin Procter LLP advised Pear Therapeutics on the deal. Pear Therapeutics announced its definitive business combination agreement with Thimble Point Acquisition Corp. (Nasdaq: THMA), a special purpose...
LumiraDx Limited’s Merger Agreement with CA Healthcare Acquisition
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its...
Markforged’s Merge With One
Goodwin Procter LLP advised Markforged on the deal, while Cadwalader advised One.Markforged announced its definitive agreement to merge with One (NYSE: AONE), a special purpose acquisition company...
Alpha Healthcare Acquisition Corp.’s $ 1.1 Billion Business Combination With Humacyte, Inc.
Goodwin Procter LLP advised Alpha Healthcare Acquisition Corp. on the deal. Covington & Burling LLP advised Humacyte, Inc. on the deal.Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC)...